Kurt Gustafson Sells 9,301 Shares of OmniAb (NASDAQ:OABI) Stock

OmniAb, Inc. (NASDAQ:OABI) CFO Kurt Gustafson sold 9,301 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $1.71, for a total transaction of $15,904.71. Following the sale, the chief financial officer owned 268,851 shares of the company’s stock, valued at approximately $459,735.21. This represents a 3.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

OmniAb Price Performance

NASDAQ OABI opened at $1.71 on Friday. The stock has a market capitalization of $246.17 million, a price-to-earnings ratio of -2.95 and a beta of 0.13. The business’s fifty day moving average price is $1.88 and its 200-day moving average price is $1.76. OmniAb, Inc. has a 1-year low of $1.22 and a 1-year high of $4.02.

Institutional Trading of OmniAb

Institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC purchased a new stake in shares of OmniAb in the 1st quarter valued at approximately $25,000. Jane Street Group LLC grew its holdings in OmniAb by 26.3% during the 1st quarter. Jane Street Group LLC now owns 80,778 shares of the company’s stock worth $194,000 after acquiring an additional 16,823 shares in the last quarter. Vanguard Personalized Indexing Management LLC acquired a new position in shares of OmniAb during the 2nd quarter worth about $79,000. Connors Investor Services Inc. boosted its holdings in OmniAb by 25.0% in the second quarter. Connors Investor Services Inc. now owns 62,000 shares of the company’s stock valued at $108,000 after purchasing an additional 12,389 shares in the last quarter. Finally, Towerview LLC grew its position in shares of OmniAb by 43.3% in the 2nd quarter. Towerview LLC now owns 831,100 shares of the company’s stock valued at $1,446,000 after buying an additional 251,100 shares during the last quarter. 72.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of OmniAb in a research note on Monday, December 22nd. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $6.67.

OmniAb Company Profile

OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.